SLIT remains under investigation in the United States. It is anticipated that many patients, who suffer from intermittent (seasonal) or persistent (perennial) allergic rhinitis, would be interested in SCIT as an immunomodulatory therapy. Not all of the future SLIT patients seek professional advice for diagnosis and treatment of allergic rhinitis or have so previously and are dissatisfied with the necessity to use or cannot tolerate pharmacotherapy. Effective SLIT (as for SCIT) requires an accurate diagnosis of IgE mediated allergic rhinitis or asthma, and it is well known that many patients are not correct when predicting what their own allergies are. The same goes for some general practice health care professionals as well!
|Original language||English (US)|
|Number of pages||3|
|Journal||Arbeiten aus dem Paul-Ehrlich-Institut (Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel) Langen/Hessen|
|State||Published - Jan 1 2013|
ASJC Scopus subject areas